Evidence map›Paper›PMID 40202965›Full record

ArticlePLOS global public health2025

Fighting tuberculosis hand in hand: A call to engage communities affected by TB as essential partners in research.

N Venkatesan, L Faust, R Lobo, H Enkh-Amgalan, T Kunor, Z Sifumba, S Rane, K O'Brien, B Kumar, C N Maimbolwa and 58 more

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

68 authors.

N VenkatesanCommunity Advisory Board, McGill International TB Centre, Montréal, Canada.
L FaustStop TB Canada Network, Ottawa, Canada.ORCID https://orcid.org/0000-0002-7610-1188
R LoboCommunity Delegation, Stop TB Partnership, Geneva, Switzerland.
H Enkh-AmgalanWorld Health Organization Civil Society Task Force on TB, Geneva, Switzerland.
T KunorWe Are TB, United States of America.
Z SifumbaTB Proof, Cape Town, South Africa.
S RaneSurvivors Against TB, Delhi, India.
K O'BrienWe Are TB, United States of America.
B KumarGlobal Coalition of TB Advocates, Delhi, India.
C N MaimbolwaCommunity Initiative for Tuberculosis, HIV/AIDS and Malaria (CITAM+), Lusaka, Zambia.
M MaytaAsociación de Personas Afectadas Por Tuberculosis (ASPAT) Péru, Lima, Peru.ORCID https://orcid.org/0000-0001-9313-6430
H PatelStop TB Canada Network, Ottawa, Canada.
L M HuongCommunity Advisory Board, Vietnam.
P HeitkampStop TB Canada Network, Ottawa, Canada.ORCID https://orcid.org/0000-0002-5530-2271
S HuddartDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.ORCID https://orcid.org/0000-0001-6425-3371
K RomanowskiMcGill University, Montréal, Canada.ORCID https://orcid.org/0000-0002-7027-3579
M HiebertUniversity of Manitoba, Winnipeg, Canada.
A J ZimmerDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada.
E L MacLeanFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0001-9272-0985
G Caceres-CardenasInstituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID https://orcid.org/0000-0003-1447-5608
L Villa CastilloDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada.ORCID https://orcid.org/0000-0002-2589-7171
J BlackThe Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, United States of America.
M BatchuStop TB United States of America, Atlanta, Georgia, United States of America.
C A TschamplThe Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-8133-4683
E ReaStop TB Canada Network, Ottawa, Canada.
T CampbellStop TB Canada Network, Ottawa, Canada.ORCID https://orcid.org/0009-0002-8480-5799
C HeffernanStop TB Canada Network, Ottawa, Canada.ORCID https://orcid.org/0000-0003-1241-7201
R LongTuberculosis Program Evaluation and Research Unit, Department of Medicine, College of Health Sciences, University of Alberta, Edmonton, Canada.
L RaithbyStop TB Canada Network, Ottawa, Canada.
A DaftarySchool of Global Health and Dahdaleh Institute of Global Health Research, York University, Toronto, Canada.
Y ChornaTB Europe Coalition, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-7940-1701
A ZhengDepartment of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-3048-3667
L MartinezDepartment of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, United States of America.
S KulkarniSection of Infectious Disease, Boston Medical Center, Boston, Massachusetts, United States of America.
C M DenkingerDepartment of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, German Center of Infection Research, partner site Heidelberg, Heidelberg, Germany.
M D M CastroDepartment of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, German Center of Infection Research, partner site Heidelberg, Heidelberg, Germany.
G SulisSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.ORCID https://orcid.org/0000-0001-6641-0094
J FurinDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
L McKennaTreatment Action Group, New York City, New York, United States of America.ORCID https://orcid.org/0000-0002-4703-0835
M FrickTreatment Action Group, New York City, New York, United States of America.
R R NathavitharanaTB Proof, Cape Town, South Africa.
C Oga-OmenkaSchool of Public Health Sciences, University of Waterloo, Waterloo, Canada.ORCID https://orcid.org/0000-0003-0779-570X
R AnanthakrishnanResource Group for Education and Advocacy for Community Health (REACH), Chennai, India.
J MalarStop TB Partnership, Geneva, Switzerland.ORCID https://orcid.org/0000-0003-1767-5218
C Ugarte-GilDepartment of Epidemiology, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas, United States of America.
W VandeveldeGlobal Network of People living with HIV (GNP+), Cape Town, South Africa.
A D KerkhoffDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.ORCID https://orcid.org/0000-0002-5023-6658
P WinarniPejuang Tangguh TB RO Jakarta (PETA), Jakarta, Indonesia.
G FoxFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
T A NguyenFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
A K J TeoFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-0569-3518
H M YapaFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
N Y PhamUniversity of Sydney Vietnam Institute, Vietnam.ORCID https://orcid.org/0000-0003-1644-4194
A RatnasinghamFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
S BernaysFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
H D TrinhFaculty of Medicine and Health, The University of Sydney, Sydney, Australia.
U KhanTBpeople Canada, Ottawa, Canada.
G G AlvarezClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
A DelucaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
M NashCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-3060-7703
O RucsineanuGlobal TB Community Advisory Board, New York City, New York, United States of America.
A VasiliuGlobal TB Program, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America.ORCID https://orcid.org/0000-0001-5336-7859
J StilloGlobal TB Community Advisory Board, New York City, New York, United States of America.
P NahidUCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.
M PaiMcGill International TB Centre, Montréal, Canada.
J JohnstonProvincial Tuberculosis Services, British Columbia Centre for Disease Control, Vancouver, Canada.ORCID https://orcid.org/0000-0002-8879-4989
A D HarriesFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0001-6113-9741
J E GolubCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-2398-3145

Funding

Feasibility and acceptability of a peer-led strategy to improve community tuberculosis case finding among non-household contacts in ZambiaK23AI157914 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KERKHOFF, ANDREW · 2021 to 2025
$999k
NIAID NIH HHS K23 AI157914World Health Organization 001
6 · The paper itself

Abstract

Tuberculosis (TB) is an infectious disease closely intertwined with stigma, discrimination, and the social determinants of health. Communities of people affected by TB are experts in their care pathways, but the TB field continues to fall short of meaningfully engaging communities in TB research. This is a missed opportunity to improve the quality, relevance, person-centeredness, positive impact, and sustainability of TB research outputs. We acknowledge the important progress that has been made to date regarding community engagement in TB, but emphasize persisting barriers to meaningful engagement, and the urgent need for updated and comprehensive TB-specific standards for such engagement in research. We highlight that core components of these standards should include the mobilisation of communities affected by TB, bilateral training in community engagement (for researchers and communities), as well as ensuring appropriate remuneration, representation of priority groups, and the use of non-stigmatising language in the engagement process. In addition, to meaningfully incorporate the experiences and expertise of communities affected by TB, their engagement in the research process should occur as early as possible, ideally before research priorities and directions are set, and the scope of the research should encompass questions and outputs relevant to the community. Further, knowledge-sharing between researchers and the community should be ensured, not only of the research outputs but also regarding the engagement process itself, so that lessons learned can be carried forward. Lastly, the sustainability of community engagement processes (whether within institutions or projects) should be ensured, including through adequate funding for such engagement and the training, community mobilisation and relationship-building that this requires.

Identifiers

PMID40202965
PMCPMC11981221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.